» Articles » PMID: 30085300

Identification of Androgen Receptor Modulators in a Prostate Cancer Cell Line Microarray Compendium

Overview
Journal Toxicol Sci
Specialty Toxicology
Date 2018 Aug 8
PMID 30085300
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

High-throughput transcriptomic (HTTr) technologies are increasingly being used to screen environmental chemicals in vitro to identify molecular targets and provide mechanistic context for regulatory testing. Here, we describe the development and validation of a novel gene expression biomarker to identify androgen receptor (AR)-modulating chemicals using a pattern matching method. Androgen receptor biomarker genes were identified by their consistent expression after exposure to 4 AR agonists and 4 AR antagonists and included only those genes that were regulated by AR. The 51 gene biomarker was evaluated as a predictive tool using the fold-change, rank-based Running Fisher algorithm. Using 158 comparisons from cells treated with 95 chemicals, the biomarker gave balanced accuracies for prediction of AR activation or AR suppression of 97% or 98%, respectively. The biomarker correctly classified 16 out of the 17 AR reference antagonists including those that are "weak" and "very weak". Predictions based on microarray profiles from AR-positive LAPC-4 cells treated with 28 chemicals in antagonist mode were compared with those from an AR pathway model which used 11 in vitro HT assays. The balanced accuracy for suppression was 93%. Using our approach, we identified conditions in which AR was modulated in a large collection of microarray profiles from prostate cancer cell lines including (1) constitutively active mutants or knockdown of AR, (2) decreases in availability of androgens by castration or removal from media, and (3) exposure to chemical modulators that work through indirect mechanisms including suppression of AR expression. These results demonstrate that the AR gene expression biomarker could be a useful tool in HTTr to identify AR modulators.

Citing Articles

A new approach methodology to identify tumorigenic chemicals using short-term exposures and transcript profiling.

Ledbetter V, Auerbach S, Everett L, Vallanat B, Lowit A, Akerman G Front Toxicol. 2024; 6:1422325.

PMID: 39483698 PMC: 11526388. DOI: 10.3389/ftox.2024.1422325.


A Collaborative Initiative to Establish Genomic Biomarkers for Assessing Tumorigenic Potential to Reduce Reliance on Conventional Rodent Carcinogenicity Studies.

Corton J, Mitchell C, Auerbach S, Bushel P, Ellinger-Ziegelbauer H, Escobar P Toxicol Sci. 2022; 188(1):4-16.

PMID: 35404422 PMC: 9238304. DOI: 10.1093/toxsci/kfac041.


A gene expression biomarker for predictive toxicology to identify chemical modulators of NF-κB.

Korunes K, Liu J, Huang R, Xia M, Houck K, Corton J PLoS One. 2022; 17(2):e0261854.

PMID: 35108274 PMC: 8809623. DOI: 10.1371/journal.pone.0261854.


A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor α in an MCF-7 Microarray Compendium.

Rooney J, Ryan N, Liu J, Houtman R, van Beuningen R, Hsieh J Chem Res Toxicol. 2021; 34(2):313-329.

PMID: 33405908 PMC: 10683854. DOI: 10.1021/acs.chemrestox.0c00243.


Mining a human transcriptome database for chemical modulators of NRF2.

Rooney J, Chorley B, Hiemstra S, Wink S, Wang X, Bell D PLoS One. 2020; 15(9):e0239367.

PMID: 32986742 PMC: 7521735. DOI: 10.1371/journal.pone.0239367.


References
1.
Lin B, Wang J, Hong X, Yan X, Hwang D, Cho J . Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS One. 2009; 4(8):e6589. PMC: 2720376. DOI: 10.1371/journal.pone.0006589. View

2.
Edwards S, Tan Y, Villeneuve D, Meek M, McQueen C . Adverse Outcome Pathways-Organizing Toxicological Information to Improve Decision Making. J Pharmacol Exp Ther. 2015; 356(1):170-81. DOI: 10.1124/jpet.115.228239. View

3.
Welsbie D, Xu J, Chen Y, Borsu L, Scher H, Rosen N . Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res. 2009; 69(3):958-66. PMC: 3219545. DOI: 10.1158/0008-5472.CAN-08-2216. View

4.
Sedelaar J, Isaacs J . Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. Prostate. 2009; 69(16):1724-9. PMC: 2784274. DOI: 10.1002/pros.21028. View

5.
Massie C, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L . The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011; 30(13):2719-33. PMC: 3155295. DOI: 10.1038/emboj.2011.158. View